Literature DB >> 34043188

Electron Microscopic Analysis of α-Synuclein Fibrils.

Airi Tarutani1,2, Masato Hasegawa3.   

Abstract

α-Synuclein (α-syn) is a major component of abnormal protein deposits observed in the brains of patients with synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy (MSA). The synaptic protein α-syn is water-soluble under normal physiological conditions, but in these patients' brains, we see accumulation of insoluble amyloid-like α-syn fibrils with prion-like properties. Intracerebral accumulation of these fibrils is correlated with disease onset and progression. Recombinant α-syn protein also forms amyloid-like fibrils that are structurally akin to those extracted from patients' brains. Recent cryo-electron microscopic studies have identified the core structures of synthetic α-syn fibrils and α-syn fibrils extracted from the brains of patients with MSA at the atomic level. In this chapter, we describe negative staining and immunoelectron microscopy protocols for ultrastructural characterization of synthetic α-syn fibrils and pathological α-syn fibrils.

Entities:  

Keywords:  Amyloid-like fibrils; Dementia with Lewy bodies; Immunoelectron microscopy; Multiple system atrophy; Negative staining; Parkinson’s disease; α-Synuclein

Year:  2021        PMID: 34043188     DOI: 10.1007/978-1-0716-1495-2_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.

Authors:  L C Serpell; J Berriman; R Jakes; M Goedert; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 2.  Alpha-synuclein and neurodegenerative diseases.

Authors:  M Goedert
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

Review 3.  Genetics of Synucleinopathies.

Authors:  Robert L Nussbaum
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

4.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; M Hasegawa; M Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 5.  Prion-like propagation of α-synuclein in neurodegenerative diseases.

Authors:  Airi Tarutani; Masato Hasegawa
Journal:  Prog Mol Biol Transl Sci       Date:  2019-07-31       Impact factor: 3.622

6.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

7.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.

Authors:  Masato Hasegawa; Hideo Fujiwara; Takashi Nonaka; Koichi Wakabayashi; Hitoshi Takahashi; Virginia M-Y Lee; John Q Trojanowski; David Mann; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2002-10-10       Impact factor: 5.157

8.  Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods.

Authors:  Airi Tarutani; Tetsuaki Arai; Shigeo Murayama; Shin-Ichi Hisanaga; Masato Hasegawa
Journal:  Acta Neuropathol Commun       Date:  2018-04-18       Impact factor: 7.801

9.  Structural and functional characterization of two alpha-synuclein strains.

Authors:  Luc Bousset; Laura Pieri; Gemma Ruiz-Arlandis; Julia Gath; Poul Henning Jensen; Birgit Habenstein; Karine Madiona; Vincent Olieric; Anja Böckmann; Beat H Meier; Ronald Melki
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  α-synuclein strains that cause distinct pathologies differentially inhibit proteasome.

Authors:  Genjiro Suzuki; Sei Imura; Masato Hosokawa; Ryu Katsumata; Takashi Nonaka; Shin-Ichi Hisanaga; Yasushi Saeki; Masato Hasegawa
Journal:  Elife       Date:  2020-07-22       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.